Despite having low response rates as monotherapy towards some tumours, everolimus has been FDA approved for the treatment of advanced renal cell carcinoma, hormone receptor-positive/HER2-negative (HR+/HER2-) breast cancer, as well as an array of neuroendocrine tumour types [61,62,63]. Here, ERBB2 is linked to neoplasm.